Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

– ARCALYST^® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –
– ARCALYST 2025 net product revenue expected to be $560 - $580 million –
– Kiniksa expects to remain cash flow positive on an annual basis –

Read more at globenewswire.com